https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Formulation Considerations for Tardive Dyskinesia Therapy

Formulation Considerations for Tardive Dyskinesia Therapy

Panelists discuss how extended-release VMAT2 inhibitor formulations improve adherence and tolerability through once-daily dosing and easier administration options, while emphasizing the importance of tailoring treatment to patient needs and the promise of emerging therapies in the pipeline.

administrator

Related Articles